Qiagen N.V. Dividend History (QGEN)
Qiagen N.V. does not pay dividends currently 😔
They might in the future, check back soon!
About Qiagen N.V.
Qiagen N.V. is a leading global provider of Sample to Insight solutions that enable customers to gain valuable insights from the building blocks of life – DNA, RNA, and proteins. Founded in 1984, the company is headquartered in Hilden, Germany. Qiagen specializes in developing and marketing a broad range of products for molecular diagnostics, academic research, and pharmaceutical and biotech industries. The company plays a vital role in advancing healthcare and research with its innovative products and technologies. As of the most recent data, Thierry Bernard serves as the CEO of Qiagen, leading the company's strategic efforts. Qiagen has consistently demonstrated strong financial performance, with substantial revenue reflecting its significant market presence and global reach.
The proteinase K market is projected to grow at a CAGR of 7.5% from 2024 to 2032, driven by the increasing prevalence of chronic and infectious diseases. The powder segment dominated the market in 2023, and the infectious diseases segment is expected to reach $795.3 million by 2032.
GlobeNewswire Inc. · Published on Thu Dec 05 2024The global sample preparation market is expected to grow at a CAGR of 6.4% by 2031, driven by technological advancements in specimen collection and preparation. The consumables segment and solid-phase extraction technique are expected to lead the market growth.
Benzinga · Published on Mon Dec 02 2024The global gene panel market is projected to reach $11.75 billion by 2031, growing at a CAGR of 19.30% during the forecast period. The market growth is driven by advancements in genomic research, rising prevalence of genetic disorders, and growing awareness of genetic testing.
GlobeNewswire Inc. · Published on Fri Nov 22 2024